Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $16.00 | Buy | Roth Capital |
| 10/6/2021 | $15.00 | Buy | Maxim Group |
Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00
Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
Ascendiant Capital analyst Edward Woo initiates coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and announces Price Target of $8.
8-K - RenovoRx, Inc. (0001574094) (Filer)
10-Q - RenovoRx, Inc. (0001574094) (Filer)
8-K - RenovoRx, Inc. (0001574094) (Filer)
SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx's Trans-Arterial Micro-Perfusion ("TAMP") therapy platform. The data was publis
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The event will be held on Tuesday, May 21, 2024. Mr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in which RenovoRx raised $17.2 million in total gross proceeds. The financing provides Reno